Mark Noviski

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Skye Montoya, Jessie Bourcier, Mark Noviski et al. · Science · 2024 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +15

IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate

Mark Noviski, James L. Mueller, Anne B. Satterthwaite et al. · eLife · 2018 · 102 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Daniel Robbins, Mark Noviski, Ying Siow Tan et al. · Journal of Medicinal Chemistry · 2024 · 96 citations · Full text

Life Sciences, Oncology, Pharmacology +17

NR4A nuclear receptors restrain B cell responses to antigen when second signals are absent or limiting

Corey Tan, Ryosuke Hiwa, James L. Mueller et al. · Nature Immunology · 2020 · 93 citations · Full text

Life Sciences, Immunology, Molecular Biology +11

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

Daniel Robbins, Mark Noviski, Ryan B. Rountree et al. · Blood · 2021 · 50 citations

Medicine, Hematology, Oncology +11